Molecule
Potassium chloride is an osmotic laxative indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. MedsAcross supplies Potassium chloride for export from India to licensed hospitals, importers and physicians acting for named patients, with the documents each country requires.
Information from the US FDA prescribing information, retrieved 12 November 2026. Not yet medically reviewed.How we review
From the regulator-approved product information. Each section names its source.
Klor-Con is indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis, in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient. KLOR-CON is a potassium salt, indicated for the treatment and prophylaxis of hypokalemia with or without metabolic alkalosis in patients for whom dietary management with potassium-rich foods or diuretic dose reduction is insufficient.
Source: US FDA prescribing information
The potassium ion is the principal intracellular cation of most body tissues. Potassium ions participate in a number of essential physiological processes including the maintenance of intracellular tonicity, the transmission of nerve impulses, the contraction of cardiac, skeletal and smooth muscle and the maintenance of normal renal function. The intracellular concentration of potassium is approximately 150 mEq to 160 mEq per liter. The normal adult plasma concentration is 3.5 mEq to 5 mEq per liter. An active ion transport system maintains this gradient across the plasma membrane. Potassium is a normal dietary constituent and under steady state conditions the amount of potassium absorbed from the gastrointestinal tract is equal to the amount excreted in the urine. The usual dietary intake of potassium is 50 to 100 mEq per day.
Source: US FDA prescribing information
Monitor serum potassium and adjust dosages accordingly. If serum potassium is less than 2.5 mEq/L, use intravenous potassium instead of oral supplementation. Take with meals and with a glass of water or other liquid. Swallow tablets whole without crushing, chewing or sucking. Treatment of hypokalemia: Doses range from 40 to 100 mEq/day in divided doses. Limit doses to 40 mEq per dose. Prevention of hypokalemia: Typical dose is 20 mEq per day.
Source: US FDA prescribing information
Potassium chloride is contraindicated in patients on triamterene and amiloride. Concomitant use with triamterene and amiloride
Source: US FDA prescribing information
Gastrointestinal Irritation: Take with meals. Gastrointestinal Adverse Reactions Solid oral dosage forms of potassium chloride can produce ulcerative and/or stenotic lesions of the gastrointestinal tract, particularly if the drug maintains contact with the gastrointestinal mucosa for prolonged periods. Consider the use of liquid potassium in patients with dysphagia, swallowing disorders, or severe gastrointestinal motility disorders. If severe vomiting, abdominal pain, distention, or gastrointestinal bleeding occurs, discontinue Klor-Con extended-release tablets and consider possibility of ulceration, obstruction or perforation. Klor-Con extended-release tablets should not be taken on an empty stomach because of its potential for gastric irritation.
Source: US FDA prescribing information
The following adverse reactions have been identified with use of oral potassium salts. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure. The most common adverse reactions to oral potassium salts are nausea, vomiting, flatulence, abdominal pain/discomfort, and diarrhea. There have been reports hyperkalemia and of upper and lower gastrointestinal condition including obstruction, bleeding, ulceration, perforation. Skin rash has been reported rarely. The most common adverse reactions are nausea, vomiting, flatulence, abdominal pain/discomfort and diarrhea.
Source: US FDA prescribing information
Triamterene and amiloride: Concomitant use is contraindicated. Renin-angiotensin-aldosterone inhibitors: Monitor for hyperkalemia. Nonsteroidal anti-inflammatory drugs: Monitor for hyperkalemia
Source: US FDA prescribing information
Store at 20° to 25°C (68° to 77°F), excursions permitted to 15° to 30°C (59° to 86°F).
Source: US FDA prescribing information
For healthcare professionals and buyers. This is not medical advice. Treatment decisions belong to the prescriber.
52 presentations of Potassium chloride, sorted by availability.
4 brand names across 1 markets.
United States
Approval facts from US FDA, EMA and CDSCO data, and registration status by country where we hold register data.
| Register | Status | Source |
|---|---|---|
| US FDA | First approved 25 April 1975 | Drugs@FDA |
| EU (EMA) | Not recorded | — |
| India (CDSCO) | Not yet confirmed against CDSCO approval lists | — |
| United States | Registered | US FDA (NDC directory, openFDA)Checked 12 November 2026 |
Conditions linked to Potassium chloride in public data. This is not a list of approved uses, see the clinical information.
Yes, on request. MedsAcross lists 52 presentations of Potassium chloride and sources them for licensed hospitals, importers and physicians against valid import documents.
The catalogue lists 4 brand names for Potassium chloride, including Klor-con, Klor-con M, Pokonza, POKONZA potassium chloride.
Yes. The US FDA first approved Potassium chloride on 25 April 1975, according to Drugs@FDA.
No listed presentation of Potassium chloride is recorded as needing a cold chain. Storage conditions are shown on each presentation page.
Potassium chloride is classified under ATC code A12BA01 (Potassium chloride).
Tell us the strength, quantity and destination country. Our team replies with availability, lead time and the import documents needed.